Novo Nordisk CEO Defends Lawsuit Against Eli Lilly: 'Competition Has to Be Fair'
Doustdar said Lilly’s ads rely on older Wegovy doses as Novo says its newer 7.2 mg results show about 19% weight loss over 72 weeks.
6 Articles
6 Articles
BURTIS: Follow the Science, Restore Medicaid Coverage for GLP-1s for Obesity
As a physician treating the chronic disease of obesity for patients across New England, including New Hampshire, I strongly urge New Hampshire’s state leaders to reconsider their decision to eliminate Medicaid coverage for GLP-1 medications to treat obesity. Patients for whom I’ve prescribed GLP-1s, such as Zepbound and Wegovy, finally found a path to weight loss and improved health that were previously unavailable with diet and exercise alone. …
Novo Nordisk's Defensive Posture: A Market Leader Fighting on Multiple Fronts
The chief executive’s choice of words on Friday was telling. “The obesity market is not a zero-sum game,” Mike Doustdar told Reuters, reaching for an analogy from the company’s own history — a dozen insulin brands once coexisted, so why not the same for GLP-1 therapies? It is the kind of reassurance a company typically […] The post Novo Nordisk’s Defensive Posture: A Market Leader Fighting on Multiple Fronts appeared first on NewsCase.
Novo Nordisk and Amazon Web Services (AWS) have announced a strategic partnership to accelerate drug discovery and modernize Novo Nordisk's business operations using agent-based AI and cloud technologies. As part of the partnership, Novo Nordisk...
Coverage Details
Bias Distribution
- 34% of the sources lean Left, 33% of the sources are Center, 33% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
